Completion of accrual for Thoracic Surgical Oncology Group 102: One small step forward for thoracic clinical trials
The inception of the Thoracic Surgical Oncology Group (TSOG) by the American Association for Thoracic Surgery addressed a long-standing need for a new organizational network to support the development and conduct of multicenter, surgically focused clinical trials in thoracic malignancies.1 Among the first studies to be launched by TSOG was a prospective cohort study examining the outcomes of patients with multifocal ground glass opacities (GGOs) —TSOG 102 (NCT03802981)—which has now reached its target accrual and officially closed to accrual in October 2023.
Source: The Journal of Thoracic and Cardiovascular Surgery - Category: Cardiovascular & Thoracic Surgery Authors: James Huang, David R. Jones, Thoracic Surgical Oncology Group 102 Investigators, Thoracic Surgical Oncology Group Executive Board Tags: Editorial Source Type: research
More News: Cancer & Oncology | Cardiology | Cardiovascular | Cardiovascular & Thoracic Surgery | Clinical Trials | Heart | Study